See more : Bigtincan Holdings Limited (BTH.AX) Income Statement Analysis – Financial Results
Complete financial analysis of 908 Devices Inc. (MASS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 908 Devices Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Dicerna Pharmaceuticals, Inc. (DRNA) Income Statement Analysis – Financial Results
- Essential Energy Services Ltd. (ESN.TO) Income Statement Analysis – Financial Results
- Avangrid, Inc. (AGR) Income Statement Analysis – Financial Results
- ZST Digital Networks, Inc. (ZSTN) Income Statement Analysis – Financial Results
- Milkfood Limited (MLKFOOD.BO) Income Statement Analysis – Financial Results
908 Devices Inc. (MASS)
About 908 Devices Inc.
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 50.23M | 46.85M | 42.21M | 26.89M | 17.97M | 22.05M |
| Cost of Revenue | 24.91M | 20.83M | 18.97M | 11.97M | 9.83M | 9.66M |
| Gross Profit | 25.32M | 26.02M | 23.23M | 14.92M | 8.14M | 12.39M |
| Gross Profit Ratio | 50.41% | 55.54% | 55.05% | 55.49% | 45.31% | 56.19% |
| Research & Development | 21.90M | 17.53M | 13.07M | 8.24M | 8.99M | 9.53M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 46.18M | 43.88M | 32.24M | 12.50M | 11.29M | 9.30M |
| Other Expenses | 0.00 | 1.82M | 386.00K | -6.03M | 301.00K | 50.00K |
| Operating Expenses | 68.08M | 61.41M | 45.30M | 20.74M | 20.29M | 18.83M |
| Cost & Expenses | 92.99M | 82.23M | 64.28M | 32.71M | 30.12M | 28.49M |
| Interest Income | 6.48M | 2.03M | 500.00K | 100.00K | 200.00K | 0.00 |
| Interest Expense | 201.00K | 129.00K | 486.00K | 976.00K | 1.53M | 1.15M |
| Depreciation & Amortization | 2.38M | 1.61M | 925.00K | 831.00K | 900.00K | 896.00K |
| EBITDA | -34.03M | -31.82M | -20.94M | -11.01M | -10.94M | -5.49M |
| EBITDA Ratio | -67.74% | -75.52% | -51.37% | -44.04% | -60.89% | -24.91% |
| Operating Income | -42.76M | -35.38M | -22.07M | -5.82M | -12.14M | -6.44M |
| Operating Income Ratio | -85.13% | -75.52% | -52.29% | -21.62% | -67.57% | -29.20% |
| Total Other Income/Expenses | 6.15M | 1.82M | -100.00K | -7.00M | -1.23M | -1.10M |
| Income Before Tax | -36.61M | -33.56M | -22.17M | -12.82M | -13.37M | -7.54M |
| Income Before Tax Ratio | -72.89% | -71.64% | -52.53% | -47.66% | -74.41% | -34.17% |
| Income Tax Expense | -211.00K | -1.82M | -53.00K | -5.88M | 1.83M | 50.00K |
| Net Income | -36.40M | -31.74M | -22.12M | -6.94M | -15.20M | -7.54M |
| Net Income Ratio | -72.47% | -67.75% | -52.40% | -25.79% | -84.60% | -34.17% |
| EPS | -1.13 | -1.01 | -0.79 | -0.25 | -0.58 | -0.40 |
| EPS Diluted | -1.13 | -1.01 | -0.79 | -0.25 | -0.58 | -0.40 |
| Weighted Avg Shares Out | 32.21M | 31.49M | 27.96M | 27.27M | 26.20M | 18.98M |
| Weighted Avg Shares Out (Dil) | 32.24M | 31.49M | 27.96M | 27.27M | 26.20M | 18.98M |
908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares' Fully Integrated Cell Therapy Manufacturing Platform
BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #bioprocessing--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and commercial-scale...
908 Devices to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences. Cowen 44th Annual Healthcare Conference, Boston, MA Fireside chat on Wednesday,...
908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2023 before market open on Tuesday, March 5,...
908 Devices Inc. (MASS) Upgraded to Buy: What Does It Mean for the Stock?
908 Devices Inc. (MASS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street
Cathie Wood's Ark Invest has been at the center of the thematic investing revolution. Two of Wood's healthcare picks, 908 Devices and Beam Therapeutics, have garnered lofty price targets from analysts.
How Much Upside is Left in 908 Devices Inc. (MASS)? Wall Street Analysts Think 100.39%
The consensus price target hints at a 100.4% upside potential for 908 Devices Inc. (MASS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq. However, the small-to-mid cap index appears to be closing the gap.
908 Devices Announces MX908 Integration Capabilities
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced that it has expanded access to its leading trace detection technology in its handheld MX908 device through the addition...
908 Devices Inc. (MASS) Q3 2023 Earnings Call Transcript
908 Devices Inc. (NASDAQ:MASS ) Q3 2023 Earnings Call Transcript November 7, 2023 8:30 AM ET Company Participants Kelly Gura - IR Kevin Knopp - Co-Founder, CEO, President & Director Joseph Griffith - CFO & Treasurer Conference Call Participants Steven...
908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended September 30, 2023. "We are pleased with the step-up in our revenues from...
Source: https://incomestatements.info
Category: Stock Reports